Cagrilintide: A Novel Acylated Amylin Analogue for Weight Management and Obesity Research
Exploring the potential of Cagrilintide in revolutionizing weight loss and obesity treatment.
Get a Quote & SampleProduct Core Value
Cagrilintide
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acting as a nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. It is recognized for its significant role in promoting weight loss and reducing food intake, positioning it as a key compound in the research of obesity.
- Discover the potential of Cagrilintide for weight loss through advanced peptide therapeutics.
- Understand the mechanism of action of amylin receptor agonists in metabolic regulation.
- Explore the research into calcitonin receptor agonists for treating metabolic disorders.
- Learn about sourcing high-quality peptide powder for effective weight management solutions.
Key Advantages
High Purity
Ensuring >99% purity for reliable and effective outcomes in obesity research and weight management applications, backed by COA and DMF documentation.
Investigational Compound
As a novel acylated amylin analogue, Cagrilintide offers unique pathways for addressing obesity and related metabolic challenges.
GMP Certified Production
Produced in Pharmaceutical GMP Plants, guaranteeing adherence to stringent quality and safety standards for research and development.
Key Applications
Obesity Research
Investigating the efficacy of Cagrilintide in preclinical and clinical studies to understand its impact on body weight regulation.
Weight Management
Utilizing Cagrilintide as a therapeutic agent to help individuals achieve and maintain a healthy body weight.
Metabolic Syndrome Treatment
Exploring the role of amylin receptor agonists in managing conditions associated with metabolic syndrome.
Pharmaceutical Intermediate
As a key component in the development of new pharmaceutical drugs targeting metabolic disorders.